Quantitative Analysis of the Enzymes Associated with 5-Fluorouracil Metabolism in Prostate Cancer Biopsies

Methods in Molecular Biology

Volumn 755, Issue , 2011, Pages 301-305

  Tanaka, Tomoaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 FU; Dihydropyrimidine dehydrogenase; Laser cutting microdissection; Orotate phosphoribosyl transferase; Prostate cancer; RT PCR

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE;

ARTICLE; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LASER; MALE; METABOLISM; METHODOLOGY; MICRODISSECTION; NEOPLASM; PROSTATE TUMOR; TISSUE FIXATION;

DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; GENE EXPRESSION; HUMANS; LASERS; MALE; MICRODISSECTION; NEOPLASMS, HORMONE-DEPENDENT; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROSTATIC NEOPLASMS; RNA, MESSENGER; TISSUE FIXATION;

EID: 79960961778     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-163-5_25     Document Type: Chapter

References (15)

1. Longley, D. B., Harkin, D. P., and Johnston, P. G. (2003) 5-fluorouracil: mechanisms of action and clinical strategies, Nat Rev Cancer 3, 330–338.
2. Miyake, H., Hara, I., Yamazaki, H., and Eto, H. (2005) Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer, Oncol Rep 14, 673–676.
3. Bhandari, M. S., Pienta, K. J., Fardig, J., Olson, K., and Smith, D. C. (2006) Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma, Cancer 106, 1715–1721.
4. Hoshi, S., Ohyama, C., Hagisawa, S., Ono, K., Satoh, M., Saito, S., Fukuzaki, A., and Arai, Y. (2003) Complete regression of bone metastases on super bone scan, by low-dose cisplatin, UFT, diethylstilbestrol diphosphate, and dexamethasone in a patient with hormone-refractory prostate cancer, Int J Clin Oncol 8, 118–120.
5. Kubota, T. (2003) 5-fluorouracil and dihydropyrimidine dehydrogenase, Int J Clin Oncol 8, 127–131.
6. Isshi, K., Sakuyama, T., Gen, T., Nakamura, Y., Kuroda, T., Katuyama, T., and Maekawa, Y. (2002) Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU, Int J Clin Oncol 7, 335–342.
7. Oguri, T., Achiwa, H., Bessho, Y., Muramatsu, H., Maeda, H., Niimi, T., Sato, S., and Ueda, R. (2005) The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells, Lung Cancer 49, 345–351.
8. Sakamoto, E., Nagase, H., Kobunai, T., Oie, S., Oka, T., Fukushima, M., and Oka, T. (2007) Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil, Biochem Biophys Res Commun 363, 216–222.
9. Wada, Y., Yoshida, K., Suzuki, T., Mizuiri, H., Konishi, K., Ukon, K., Tanabe, K., Sakata, Y., and Fukushima, M. (2006) Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines, Int J Cancer 119, 783–791.
10. Fujii, R., Seshimo, A., and Kameoka, S. (2003) Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma, Int J Clin Oncol 8, 72–78.
11. Katsumata, K., Tomioka, H., Sumi, T., Yamashita, S., Takagi, M., Kato, F., Nakamura, R., Koyanagi, Y., Aoki, T., and Kato, K. (2003) Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens, Cancer Chemother Pharmacol 51, 155–160.
12. Birtle, A. J., Newby, J. C., and Harland, S. J. (2004) Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer, Br J Cancer 91, 1472–1476.
13. Droz, J. P., Muracciole, X., Mottet, N., Ould Kaci, M., Vannetzel, J. M., Albin, N., Culine, S., Rodier, J. M., Misset, J. L., Mackenzie, S., Cvitkovic, E., and Benoit, G. (2003) Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients, Ann Oncol 14, 1291–1298.
14. Tanaka, T., Kawashima, H., Matsumura, K., Yamashita-Hosono, T., Yoshimura, R., Kuratsukuri, K., Harimoto, K., and Nakatani, T. (2009) Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer, Oncol Rep 21, 33–37.
15. Lord, R. V., Salonga, D., Danenberg, K. D., Peters, J. H., DeMeester, T. R., Park, J. M., Johansson, J., Skinner, K. A., Chandrasoma, P., DeMeester, S. R., Bremner, C. G., Tsai, P. I., and Danenberg, P. V. (2000) Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence, J Gastrointest Surg 4, 135–142.